Rave Lite: Medidata’s New Solution for Accelerating Clinical Trials at Every Stage

October 18, 2024,New York, United States : Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Medidata Rave Lite, an extension of the company’s gold-standard clinical research software, Medidata Rave EDC, designed explicitly for Phase I and Phase IV studies. Regardless of company size, therapeutic focus, or pipeline, Rave Lite provides efficient electronic clinical data capture (EDC), management, and analysis solutions with a tailored pricing model.

While EDC is a fundamental building block of clinical trials, technology fragmentation across phases leads to integration challenges and delays in startup times. In particular, the lack of access to innovative technology disproportionately affects early- and late-stage studies. Having addressed these challenges in over 34,000 trials, Medidata is now offering superior options for Phase I and Phase IV studies with Rave Lite.

With Medidata Designer integration, study builders can design Phase I and Phase IV trials with speed and precision, and with the continued use of AI, potential study misconfigurations are reduced while securing data integrity. Thus, Rave Lite offers a consistent experience without sacrificing the advanced power of Rave EDC.

“Rave Lite addresses a critical need in the market for early and late-stage trials, offering a streamlined solution built on our trusted Rave EDC platform,” said Tom Doyle, chief technology officer, Medidata. “By giving our customers the ability to use one EDC ubiquitously across all phases, customers gain the flexibility to scale their studies while maintaining the high standards that have long defined Medidata’s solutions.”

Rave EDC was recently recognized as the leading provider by Everest Group‘s first-ever PEAK Matrix® for its effectiveness in simplifying clinical trials for sponsors and CROs while ensuring data quality and integrity.